Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

被引：1

作者：

Kaplan, David ^{[1
]}

Husni, Elaine ^{[2
]}

Chang, Eunice ^{[3
]}

S. Broder, Michael ^{[3
]}

Paydar, Caleb ^{[3
]}

Bognar, Kata ^{[3
]}

Yan, Jessie ^{[4
]}

Richter, Sven ^{[5
]}

Desai, Pooja ^{[6
]}

Khilfeh, Ibrahim ^{[7
]}

机构：

[1] Adult & Pediat Dermatol, Overland Pk, KS 66211 USA

[2] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH 44195 USA

[3] Partnership Hlth Analyt Res LLC, Beverly Hills, CA 90212 USA

[4] Roche, San Francisco, CA 94080 USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Janssen Pharmaceut, Titusville, NJ 08560 USA

[7] Janssen Pharmaceut, Raritan, NJ 08869 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2022年 / 11卷 / 08期

关键词：

administrative claims analysis; biologic initiation; DMARD; oral small molecules; PLAQUE PSORIASIS; ARTHRITIS; EFFICACY; CARE; PREDICTORS; MANAGEMENT; MODERATE; SAFETY; AGE;

D O I：

10.2217/cer-2021-0311

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37-0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2-15.7%] vs 28.6% [95% CI: 26.8-30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40-0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.

引用

页码：575 / 582

页数：8

共 50 条

[31] BIOLOGIC CHOICES AFTER FIRST-LINE ANTI-TUMOUR NECROSIS FACTOR FAILURE IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Richards, H.
Baildam, E.
McCann, L. J.
Cleary, A. G.
Beresford, M. W.
Pain, C. E.
RHEUMATOLOGY, 2014, 53 : 8 - 8
[32] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY
Liao, Donna
Aminilari, Mahmood
Tsao, May
Ahmed, Sameera
Ye, Xiang Y.
Prica, Anca
Metser, Ur
Singnurkar, Amit
Hodgson, David
RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S4 - S4
[33] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY
不详
RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S4 - S4
[34] A Comparison of Weekly DCF versus Standard DCF as First-line Systemic Chemotherapy for Metastatic Gastric Cancer Patients
Aldemir, M. N.
Turkeli, M.
Simsek, M.
Yildirim, N.
Bilici, M.
Dogan, C.
Tekin, S. B.
WEST INDIAN MEDICAL JOURNAL, 2023, 70 (01): : 18 - 22
[35] LONG-TERM PROGNOSTIC FOLLOW-UP OF PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AFTER THE CLINICAL TRIAL OF TOCILIZUMAB AS A FIRST-LINE BIOLOGIC TREATMENT
Miyamae, T.
Kawabe, T.
Nishimura, K.
Hattori, S.
Imagawa, T.
Ishii, T.
Ito, S.
Iwata, N.
Kamata, Y.
Kamiyama, Y.
Mizuta, M.
Mori, M.
Murase, A.
Nakagishi, Y.
Nakano, T.
Nakayamada, S.
Nozawa, T.
Ohya, T.
Okamoto, N.
Sato, K.
Sugita, Y.
Takei, S.
Tanaka, Y.
Tomiita, M.
Umebayashi, H.
Yamasaki, Y.
Nishimoto, N.
Yokota, S.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 671 - 672
[36] First Head-to-Head Study in Crohn's Disease supports the Use of Ustekinumab as a First-line Biological in Biological-naive Patients
不详
VISCERAL MEDICINE, 2021, 37 (04) : 326 - 326
[37] Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment
Leutz, A.
Pinter, A.
Thaci, D.
Augustin, M.
Schuster, C.
Fotiou, K.
Hundemer, H. P.
Saure, D.
Mrowietz, U.
Reich, K.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 548 - 550
[38] Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.
Nasar, Naaz
Armstrong, Misha
Chou, Joanne F.
Gonen, Mithat
Soares, Kevin
Balachandran, Vinod P.
Drebin, Jeffrey A.
Kingham, T. Peter
Wei, Alice Chia-Chi
D'Angelica, Michael Ian
Cercek, Andrea
Harding, James J.
O'Reilly, Eileen Mary
Abou-Alfa, Ghassan K.
Park, Wungki
Connell, Louise Catherine
Kemeny, Nancy E.
Jarnagin, William R.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 522 - 522
[39] COST-EFFECTIVENESS EVALUATION OF SEQUENTIAL TREATMENT STATEGIES FOR TREATMENT NAIVE PATIENTS WITH BRAF MUTANT METASTATIC MELANOMA IN UK: NIVOLUMAB PLUS IPILIMUMAB FIRST-LINE VERSUS DABRAFENIB PLUS TRAMETINIB FIRST-LINE
Tokarz, A.
Cai, R.
Baginska-Dudek, B.
Yates, G.
Srinivasan, S.
Okorogheye, G.
Palaia, J.
McDonald, L.
VALUE IN HEALTH, 2024, 27 (12) : S106 - S106
[40] Reduced risk of Efavirenz Discontinuation in Naive Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen
Fabbiani, M.
Zaccarelli, M.
Latini, A.
Sterrantino, G.
D'Ettorre, G.
Grima, P.
Mondi, A.
Rossetti, B.
Borchi, B.
Giuliani, M.
Antinori, A.
De Luca, A.
Di Giambenedetto, S.
HIV MEDICINE, 2016, 17 (05) : 385 - 389

← 1 2 3 4 5 →